Prolonged-release pirfenidone in patients with compensated cirrhosis. Final results of the multicenter study ODISEA, controlled against placebo, plus standardized care_2023 Linda E. Munoz-Espinosa; Aldo Torre; Laura Cisneros; Iaarah Montalvo-Gordon; René Malé-Velázquez; Scherezada Mejía; Juan Ramón Aguilar-Ramírez; Javier Lizardi-Cervera; María E. Icaza-Chávez; Frida Gasca-Díaz; Larissa Hernández-Hernández; Paula Cordero-Perez; Luis A. Chi-Cervera; Lilian Torres-Made; Fátima Rodríguez-Álvarez; Graciela Tapia; Jorge Luis Poo;

Factors associated with obtaining lower IQR-CAP values in the detection of hepatic steatosis by transient elastography Iván López-Mendez; Juan Luis Romero-Flores; Graciela Castro-Narro; Misael Uribe; Eva Juárez-Hernández;

P-26 EPIGENETIC MARKS IN PATIENTS WITH SUSTAINED VIRAL RESPONSE TO HCV AND RESIDUAL LIVER FIBROSIS ARE RESTORED BY PROLONGED-RELEASE PIRFENIDONE Eira Cerda Reyes; Ricardo De la Rosa Bibiano; Ana Sandoval Rodriguez; Rebeca Rosas Campos; Rebeca Escutia Gutiérrez; Ángel Omar Vázquez Esqueda; Stefanny Cornejo Hernández; Alejandro Gutiérrez Átemis; Salvador Amezquita Pérez; Jorge Luis Poo; Gildardo Agustin Garrio Sanchez; Juan Ramón Aguilar; Juan Armendáriz Borunda;